Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1613
    -0.0070 (-0.60%)
     
  • GBP/USD

    1.2371
    -0.0067 (-0.54%)
     
  • Bitcoin GBP

    52,007.30
    +875.94 (+1.71%)
     
  • CMC Crypto 200

    1,381.20
    +68.58 (+5.42%)
     
  • S&P 500

    4,965.12
    -46.00 (-0.92%)
     
  • DOW

    37,934.79
    +159.41 (+0.42%)
     
  • CRUDE OIL

    83.38
    +0.65 (+0.79%)
     
  • GOLD FUTURES

    2,410.30
    +12.30 (+0.51%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Merged Al Noor/Mediclinic to list on Feb 15, eyes Gulf expansion

(Adds details)

By Stanley Carvalho

ABU DHABI, Feb 2 (Reuters) - Mediclinic International Plc, which is being created by the merger of Al Noor Hospitals Group and Mediclinic International Ltd, will be listed in London on Feb. 15, the chief executive of Al Noor said on Tuesday.

The combination, announced in October, will create the third-largest international healthcare group outside the United States, according to Al Noor CEO Ronald Lavater, after South Africa's Mediclinic agreed to buy United Arab Emirates-based Al Noor for 1.4 billion pounds ($2.2 billion).

The deal was structured as a so-called reverse takeover with Mediclinic set to take on Al Noor's London listing as it primary listing. Current Al Noor shareholders have until Feb. 12 to decide whether to swap their shares under a tender offer which will see Mediclinic ultimately own between 84 and 93 percent of the combined company.

ADVERTISEMENT

"All approvals are done, all paper work signed and the listing and final change of control is on Feb. 15," Lavater told Reuters.

The integration process will start soon after listing and will be done in phases, with the first wave focused on achieving synergies in purchases and service contracts, he said.

The next phase would look at synergies in clinical practice and medical services, locations for hospitals and deployment of capital.

"From the growth perspective, each of us were looking at growth in each other's markets," said Lavater. He declined to outline the new growth strategy but said that in the Middle East, the combined company would focus on expansion in the UAE.

Mediclinic has been on an acquisition spree - it bought almost a third Britain's Spire Healthcare (LSE: SPI.L - news) in June - as it seeks to diversify outside its home market where a government probe into private hospitals and a mooted national health insurance plan is limiting growth opportunities.

Like much of the Gulf region, the UAE healthcare market is booming due to an increasingly-wealthy population being burdened by high levels of lifestyle diseases, such as diabetes.

Both Al Noor and Mediclinic had been expanding in the UAE, building new hospitals and clinics, and this will continue under the combined entity, according to Lavater.

"There are lots of opportunities for high-quality healthcare in the UAE and unmet needs in Saudi Arabia, Oman and Qatar that could be expanded by the enlarged group in the future," he said.

In the UAE, both the Al Noor and Mediclinic brands will be retained on their existing centres. The merged company will have 73 hospitals, 35 clinics, over 10,000 beds and around 35,000 employees across South Africa, UAE and Switzerland. (Reporting by Stanley Carvalho; Editing by David French and Mark Potter)